<aside> 💡
If you’re staring at a list of preclinical biotechs and thinking - “Which ones are actually a fit, and why, and how could I best reach out?” - this approach below is perfect!
Here’s in 3 minutes how to do it:
https://www.youtube.com/watch?v=8oFnQ1CghqA&list=PLWkBzvjDToJ2SuT_NgwK6id6kho66B9Fa&index=1
</aside>
<aside> 💡
Q1: Do you see signals that this company most likely will need a CDMO soon? Answer with Yes or No or Unclear.
Yes
Q2: If yes, specify those signals.
Q3: Based on our strengths and offers as described below, how well of a fit is this group for our offers? Answer with “Excellent fit”, “Good fit”, “Poor fit”, or “Unclear fit”.
Excellent fit
Q4: Justify in bullets why.
Q5: Describe the stage of the company in 1 sentence
EvolveImmune is a clinical-stage immunotherapy startup expecting to enter first-in-human trials in 2025, with a lead internal asset and a major pharma collaboration, targeting development and IND-enabling activities for sophisticated multispecific biologics.[Source]
Q6: Describe the stage of the most advanced ADC asset with in bullet points details on Modality, Submodality, TA, indication, target, MOA, ROA.
Q7: Describe the scientific validation of the most advanced asset in 2 sentences
Preclinical studies show that EVOLVE205 displays significantly superior cytotoxicity and tumor-killing potency (up to 70-fold vs. Glofitamab, >1000-fold vs. Rituximab) in B cell lymphoma models, while minimizing cytokine release and demonstrating a favorable biochemical developability profile. In vivo efficacy in xenograft models supports its potential as a best-in-class T cell engager with integrated costimulation for hematological cancers.[Source]
Q8: Do you see any indication if they already work with a CDMO? Specify
No explicit evidence in the provided materials of a current CDMO relationship; the AbbVie partnership may entail CMC/mfg support, but no public CDMO partner is named.[Source]
Q9: Write me 3 short highly tailored cold emails as part of an email sequence linking needs that they most likely will have with our unique offers.
Email 1 – “Accelerate Your Clinic Entry”
Subject: Supporting EvolveImmune’s Leap into the Clinic in 2025
Hi [Name],
Congratulations on the progress with your EVOLVE platform and the exciting clinical plans for 2025. Lonza’s proven experience in scaling and manufacturing complex multispecific antibodies for clinical trials uniquely positions us to accelerate your lead program’s transition to the clinic, ensuring robust, GMP-compliant supply. Would you be open to a brief call to discuss how we could help with IND-enabling and clinical manufacturing for EVOLVE104?
Email 2 – “Optimizing Trispecific Biologic Manufacturing”
Subject: End-to-End Solutions for Next-Gen T Cell Engagers
Hi [Name],
With your focus on novel trispecifics that integrate CD2 costimulation, you’ll likely need customized process development and analytical support to address unique engineering challenges. Lonza’s state-of-the-art platforms and deep analytical expertise enable seamless scale-up of even the most complex multispecific biologics—helping emerging innovators like EvolveImmune de-risk and expedite CMC milestones. Let’s explore your CMC journey and how we can accelerate your pipeline assets.
Email 3 – “Partnering for Seamless Scale-Up and CMC Success”
Subject: Strategic CDMO Partnership for EvolveImmune’s Pipeline
Hi [Name],
As you advance multiple programs—both internal and partnered—it’s crucial to have a CDMO partner that can flexibly meet your needs from discovery through to commercialization. Lonza’s global biologics platforms, now enhanced with Synaffix ADC technologies, can support your efforts with integrated process development, scale-up, and regulatory know-how across TCEs, ADCs, and multispecifics. Are you available next week for an introduction to our tailored solutions?
Q10: Write me a short tailored and compelling message I could use on Linkedin or a partnering tool to try and get a meeting to explore how we can best help.
Hi [Name],
Congrats on advancing EvolveImmune’s trispecific T cell engager pipeline toward the clinic. I’d love to connect and share how Lonza’s specialized manufacturing platforms (including for complex multispecifics and ADCs) can help de-risk and expedite your CMC journey—supporting your IND/clinical milestones and rapid scale-up. Can we arrange a short call to discuss how we can partner for success?
</aside>
Go to a profile → Click on the Edit button in Ask Anything (see screenshot below)
See here the text to copy paste:
Q1: Do you see signals that this company most likely will need a CDMO soon? Answer with Yes or No or Unclear. Q2: If yes, specify those signals. Q3: Based on our strengths and offers as described below, how well of a fit is this group for our offers? Answer with “Excellent fit”, “Good fit”, “Poor fit”, or “Unclear fit”. Q4: Justify in bullets why. Q5: Describe the stage of the company in 1 sentence Q6: Describe the stage of the most advanced trispecifics asset with in bullet points details on Modality, Submodality, TA, indication, target, MOA, ROA. Q7: Describe the scientific validation of the most advanced asset in 2 sentences Q8: Do you see any indication if they already work with a CDMO? Specify Q9: Write me 3 short highly tailored cold emails as part of an email sequence linking needs that they most likely will have with our unique offers. Q10: Write me a short tailored and compelling message I could use on Linkedin or a partnering tool to try and get a meeting to explore how we can best help. Answer each question on a new line
Here's info on our offerings: (copy paste info on your offering here)